Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced participation in two upcoming investor conferences. The 29th Annual Credit Suisse Virtual Healthcare Conference is on November 9 at 5 p.m. Eastern Time, and the Barclays Gene Editing & Gene Therapy Summit is scheduled for November 16 at 10:45 a.m. Eastern Time. Both presentations will be webcast live and later available on their website under the Investors and Media section. Sangamo focuses on advancing genomic medicines through gene therapy and genome editing.
Sangamo Therapeutics reported Q3 2020 financial results, showing revenues of $57.8 million, up from $22.0 million in Q3 2019. The company achieved a $30 million milestone from Pfizer for dosing the first patient in the Phase 3 AFFINE study for hemophilia A gene therapy. Cash and equivalents increased to $694.6 million. Despite a net loss of $1.6 million (or $0.01 per share), down from a loss of $27.3 million in the prior year, operating expenses rose to $61.5 million. The company revised its operating expense guidance for 2020 to $210 to $220 million.
Sangamo Therapeutics (Nasdaq: SGMO) has announced the release date for its third quarter 2020 financial results, set for November 4, 2020, after market close. A conference call will follow at 5:00 p.m. ET, where financial results and business updates will be discussed. Interested participants can join via telephone or webcast, with specific dial-in numbers provided for domestic and international callers. A replay of the conference call will be available for one week thereafter.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced its participation in two upcoming investor conferences. The Jefferies Virtual Gene Therapy / Editing Summit will take place on October 1st at 12:00 PM ET, followed by the Chardan Genetic Medicines Conference on October 5th at 8:00 AM ET. Both presentations will be webcast live and accessible via the Sangamo website's Investors and Media section. The company's focus is on developing genomic medicines, including gene therapy and genome editing.